Skip to main content
Erschienen in: Diabetology International 2/2022

20.10.2021 | Original Article

Effects of barley intake on glycemic control in Japanese patients with type 2 diabetes mellitus undergoing antidiabetic therapy: a prospective study

verfasst von: Takeshi Osonoi, Tsubasa Matsuoka, Kensuke Ofuchi, Makoto Katoh, Toshiki Kobayashi, Kazuki Mochizuki

Erschienen in: Diabetology International | Ausgabe 2/2022

Einloggen, um Zugang zu erhalten

Abstract

Background

Barley reportedly reduces postprandial hyperglycemia in healthy individuals. However, its effects in patients with type 2 diabetes mellitus (T2DM) undergoing antidiabetic therapy remains unclear. This study aimed to clarify the effects of barley intake on postprandial hyperglycemia in T2DM patients who use metformin or acarbose.

Methods

T2DM patients who were undergoing dietary therapy without medications (naive), with metformin, or with acarbose (n = 10/group) were recruited. They were instructed to eat white rice twice per day for 5 days, followed by barley-mixed rice twice per day for 6 or 7 days. Subsequently, blood glucose fluctuations in the interstitial fluid glucose were measured using a continuous glucose monitoring device. Meal tolerance tests were performed using test diets containing white rice and barley-mixed rice before and after the trial, respectively.

Results

Postprandial hyperglycemia was lower in patients taking barley-mixed rice than in those taking white rice in each group. However, the AUC of blood glucose concentration in the acarbose-treated patients showed only a trend. Mean amplitude of glycemic excursions (MAGEs) decreased in patients who consumed barley-mixed rice. Additionally, although MAGEs in the naive decreased, it did not in the metformin- (P = 0.098) and acarbose-treated (P = 0.29) patients.

Conclusion

Barley-mixed rice lowers postprandial glucose concentrations in treatment-naive and metformin-treated T2DM patients, and shows a trend in acarbose-treated patients. Therefore, using barley-containing diets as dietary therapy may be useful in improving glycemic control in diabetes patients.

Trial registration

UMIN000028623.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Patel V. Diabetes mellitus: the disease. Diabetic eye disease, Japan diabetes society 2016th–2017th edition. New York: Elsevier; 2000. p. 1–24. Patel V. Diabetes mellitus: the disease. Diabetic eye disease, Japan diabetes society 2016th–2017th edition. New York: Elsevier; 2000. p. 1–24.
2.
Zurück zum Zitat Oizumi T, Daimon M, Jimbu Y, Wada K, Kameda W, Susa S, Yamaguchi H, Ohnuma H, Tominaga M, Kato T. Impaired glucose tolerance is a risk factor for stroke in a Japanese sample-the Funagata study. Metabolism. 2008;57:333–8.CrossRef Oizumi T, Daimon M, Jimbu Y, Wada K, Kameda W, Susa S, Yamaguchi H, Ohnuma H, Tominaga M, Kato T. Impaired glucose tolerance is a risk factor for stroke in a Japanese sample-the Funagata study. Metabolism. 2008;57:333–8.CrossRef
3.
Zurück zum Zitat DECODE Study Group, European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:617–21.CrossRef DECODE Study Group, European Diabetes Epidemiology Group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet. 1999;354:617–21.CrossRef
4.
Zurück zum Zitat Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group, STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486–94.CrossRef Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M, STOP-NIDDM Trial Research Group, STOP-NIDDM Trial Research Group. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA. 2003;290:486–94.CrossRef
5.
Zurück zum Zitat Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–6.CrossRef Hanefeld M, Cagatay M, Petrowitsch T, Neuser D, Petzinna D, Rupp M. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J. 2004;25:10–6.CrossRef
6.
Zurück zum Zitat Liu S, Willett WC, Stampfer MJ, Hu FB, Hu FB, Franz M, Sampson L, Hennekens CH, Manson JE. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr. 2000;71:1455–61.CrossRef Liu S, Willett WC, Stampfer MJ, Hu FB, Hu FB, Franz M, Sampson L, Hennekens CH, Manson JE. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr. 2000;71:1455–61.CrossRef
7.
Zurück zum Zitat Fung TT, Hu FB, Pereira MA, Liu S, Stampfer MJ, Colditz GA, Willett WC. Whole-grain intake and the risk of type 2 diabetes: a prospective study in men. Am J Clin Nutr. 2002;76:535–40.CrossRef Fung TT, Hu FB, Pereira MA, Liu S, Stampfer MJ, Colditz GA, Willett WC. Whole-grain intake and the risk of type 2 diabetes: a prospective study in men. Am J Clin Nutr. 2002;76:535–40.CrossRef
8.
Zurück zum Zitat Foster-Powell K, Holt SHA, Brand-Miller JC. International table of glycemic index and glycemic load values. Am J Clin Nutr. 2002;76:5–56.CrossRef Foster-Powell K, Holt SHA, Brand-Miller JC. International table of glycemic index and glycemic load values. Am J Clin Nutr. 2002;76:5–56.CrossRef
9.
Zurück zum Zitat Sun Q, Spiegelman D, van Dam RM, Holmes MD, Malik VS, Willett WC, Hu FB. White rice, brown rice, and risk of type 2 diabetes in US men and women. Arch Intern Med. 2010;170:961–9.CrossRef Sun Q, Spiegelman D, van Dam RM, Holmes MD, Malik VS, Willett WC, Hu FB. White rice, brown rice, and risk of type 2 diabetes in US men and women. Arch Intern Med. 2010;170:961–9.CrossRef
10.
Zurück zum Zitat Sakuma M, Yamanaka-okumura H, Naniwa Y, Matsumoto D, Tsunematsu M, Yamamoto H, Taketani Y, Takeda E. Dose-dependent effects of barley cooked with white rice on postprandial glucose and desacyl ghrelin levels. J Clin Biochem Nutr. 2009;44:151–9.CrossRef Sakuma M, Yamanaka-okumura H, Naniwa Y, Matsumoto D, Tsunematsu M, Yamamoto H, Taketani Y, Takeda E. Dose-dependent effects of barley cooked with white rice on postprandial glucose and desacyl ghrelin levels. J Clin Biochem Nutr. 2009;44:151–9.CrossRef
11.
Zurück zum Zitat Higa M, Fuse Y, Miyashita N, Fujitani A, Yamashita K, Ichijo T, Aoe S, Hirose T. Effect of high β-glucan barley on postprandial blood glucose levels in subjects with normal glucose tolerance: assessment by meal tolerance test and continuous glucose monitoring system. Clin Nutr Res. 2019;8:55–63.CrossRef Higa M, Fuse Y, Miyashita N, Fujitani A, Yamashita K, Ichijo T, Aoe S, Hirose T. Effect of high β-glucan barley on postprandial blood glucose levels in subjects with normal glucose tolerance: assessment by meal tolerance test and continuous glucose monitoring system. Clin Nutr Res. 2019;8:55–63.CrossRef
12.
Zurück zum Zitat Bouza C, López-Cuadrado T, Gutierrez-Torres LF, Amate J. Efficacy and safety of metformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta-analysis. Obes Facts. 2012;5:753–65.CrossRef Bouza C, López-Cuadrado T, Gutierrez-Torres LF, Amate J. Efficacy and safety of metformin for treatment of overweight and obesity in adolescents: an updated systematic review and meta-analysis. Obes Facts. 2012;5:753–65.CrossRef
13.
Zurück zum Zitat Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019;18:1–16.CrossRef Han Y, Xie H, Liu Y, Gao P, Yang X, Shen Z. Effect of metformin on all-cause and cardiovascular mortality in patients with coronary artery diseases: a systematic review and an updated meta-analysis. Cardiovasc Diabetol. 2019;18:1–16.CrossRef
14.
Zurück zum Zitat Kobayashi T, Kaneko S, Matsuoka T. The effect of barley noodles on blood sugar levels in type 2 diabetes patients. J Japanese Assoc Diet Fiber Res. 2013;17:35–40. Kobayashi T, Kaneko S, Matsuoka T. The effect of barley noodles on blood sugar levels in type 2 diabetes patients. J Japanese Assoc Diet Fiber Res. 2013;17:35–40.
15.
Zurück zum Zitat Matsuoka T, Uchimatsu D, Kobayashi T, Aoe S. Effect of barley on metabolic syndrome related indicators in overweight Japanese men and women. J Japanese Assoc Diet Fiber Res. 2014;18:25–33. Matsuoka T, Uchimatsu D, Kobayashi T, Aoe S. Effect of barley on metabolic syndrome related indicators in overweight Japanese men and women. J Japanese Assoc Diet Fiber Res. 2014;18:25–33.
16.
Zurück zum Zitat Aoe S, Ichinose Y, Kohyama N, Komae K, Takahashi A, Abe D, Yoshioka T, Yanagisawa T. Effects of high β-glucan barley on visceral fat obesity in Japanese individuals: a randomized, double-blind study. Nutrition. 2017;42:1–6.CrossRef Aoe S, Ichinose Y, Kohyama N, Komae K, Takahashi A, Abe D, Yoshioka T, Yanagisawa T. Effects of high β-glucan barley on visceral fat obesity in Japanese individuals: a randomized, double-blind study. Nutrition. 2017;42:1–6.CrossRef
Metadaten
Titel
Effects of barley intake on glycemic control in Japanese patients with type 2 diabetes mellitus undergoing antidiabetic therapy: a prospective study
verfasst von
Takeshi Osonoi
Tsubasa Matsuoka
Kensuke Ofuchi
Makoto Katoh
Toshiki Kobayashi
Kazuki Mochizuki
Publikationsdatum
20.10.2021
Verlag
Springer Singapore
Erschienen in
Diabetology International / Ausgabe 2/2022
Print ISSN: 2190-1678
Elektronische ISSN: 2190-1686
DOI
https://doi.org/10.1007/s13340-021-00552-z

Weitere Artikel der Ausgabe 2/2022

Diabetology International 2/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Bei Herzinsuffizienz muss „Eisenmangel“ neu definiert werden!

16.05.2024 Herzinsuffizienz Nachrichten

Bei chronischer Herzinsuffizienz macht es einem internationalen Expertenteam zufolge wenig Sinn, die Diagnose „Eisenmangel“ am Serumferritin festzumachen. Das Team schlägt vor, sich lieber an die Transferrinsättigung zu halten.

Herzinfarkt mit 85 – trotzdem noch intensive Lipidsenkung?

16.05.2024 Hypercholesterinämie Nachrichten

Profitieren nach einem akuten Myokardinfarkt auch Betroffene über 80 Jahre noch von einer intensiven Lipidsenkung zur Sekundärprävention? Um diese Frage zu beantworten, wurden jetzt Registerdaten aus Frankreich ausgewertet.

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.